Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine

Background: Studies reporting the long-term humoral response after receiving the BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet, available literature is scarce. Covidiagnostix is a multicenter study designed to assess the antibody response in >1000 healthcare...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davide Ferrari, Nicola Clementi, Elena Criscuolo, Alessandro Ambrosi, Francesca Corea, Chiara Di Resta, Rossella Tomaiuolo, Nicasio Mancini, Massimo Locatelli, Mario Plebani, Giuseppe Banfi
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 serological test mRNA vaccine Roche Anti-SARS-CoV-2-S immune response vaccination Medicine R
Acceso en línea:	https://doaj.org/article/2a53109e5c4446eab4133351448890e3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a53109e5c4446eab4133351448890e3
record_format	dspace
spelling	oai:doaj.org-article:2a53109e5c4446eab4133351448890e32021-11-25T19:11:36ZAntibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine10.3390/vaccines91113572076-393Xhttps://doaj.org/article/2a53109e5c4446eab4133351448890e32021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1357https://doaj.org/toc/2076-393XBackground: Studies reporting the long-term humoral response after receiving the BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet, available literature is scarce. Covidiagnostix is a multicenter study designed to assess the antibody response in >1000 healthcare professionals (HCPs) who received the BNT162b2 vaccine. Methods: Serum was tested at time-0 (T<sub>0</sub>), before the first dose, T<sub>1</sub>, T<sub>2,</sub> and T<sub>3</sub>, respectively, 21, 42, and 180 days after T<sub>0</sub>. Antibodies against the SARS-CoV-2 nucleocapsid-protein were measured to assess SARS-CoV-2 infections, whereas antibodies against the receptor-binding domain of the spike protein were measured to assess the vaccine response. Neutralization activity against the D614G, B.1.1.7, and B.1.351 variants were also analyzed. Results: Six months post-vaccination HCPs showed an antibody titer decrease of approximately 70%, yet, the titer was still one order of magnitude higher than that of seropositive individuals before vaccination. We identified 12 post-vaccination infected HCPs. None showed severe symptoms. Interestingly, most of them showed titers at T<sub>2</sub> above the neutralization thresholds obtained from the neutralization activity experiments. Conclusion: Vaccination induces a humoral response which is well detectable even six months post-vaccination. Vaccination prevents severe COVID-19 cases, yet post-vaccination infection is possible even in the presence of a high anti-S serum antibody titer.Davide FerrariNicola ClementiElena CriscuoloAlessandro AmbrosiFrancesca CoreaChiara Di RestaRossella TomaiuoloNicasio ManciniMassimo LocatelliMario PlebaniGiuseppe BanfiMDPI AGarticleCOVID-19serological testmRNA vaccineRoche Anti-SARS-CoV-2-Simmune responsevaccinationMedicineRENVaccines, Vol 9, Iss 1357, p 1357 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 serological test mRNA vaccine Roche Anti-SARS-CoV-2-S immune response vaccination Medicine R
spellingShingle	COVID-19 serological test mRNA vaccine Roche Anti-SARS-CoV-2-S immune response vaccination Medicine R Davide Ferrari Nicola Clementi Elena Criscuolo Alessandro Ambrosi Francesca Corea Chiara Di Resta Rossella Tomaiuolo Nicasio Mancini Massimo Locatelli Mario Plebani Giuseppe Banfi Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
description	Background: Studies reporting the long-term humoral response after receiving the BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet, available literature is scarce. Covidiagnostix is a multicenter study designed to assess the antibody response in >1000 healthcare professionals (HCPs) who received the BNT162b2 vaccine. Methods: Serum was tested at time-0 (T<sub>0</sub>), before the first dose, T<sub>1</sub>, T<sub>2,</sub> and T<sub>3</sub>, respectively, 21, 42, and 180 days after T<sub>0</sub>. Antibodies against the SARS-CoV-2 nucleocapsid-protein were measured to assess SARS-CoV-2 infections, whereas antibodies against the receptor-binding domain of the spike protein were measured to assess the vaccine response. Neutralization activity against the D614G, B.1.1.7, and B.1.351 variants were also analyzed. Results: Six months post-vaccination HCPs showed an antibody titer decrease of approximately 70%, yet, the titer was still one order of magnitude higher than that of seropositive individuals before vaccination. We identified 12 post-vaccination infected HCPs. None showed severe symptoms. Interestingly, most of them showed titers at T<sub>2</sub> above the neutralization thresholds obtained from the neutralization activity experiments. Conclusion: Vaccination induces a humoral response which is well detectable even six months post-vaccination. Vaccination prevents severe COVID-19 cases, yet post-vaccination infection is possible even in the presence of a high anti-S serum antibody titer.
format	article
author	Davide Ferrari Nicola Clementi Elena Criscuolo Alessandro Ambrosi Francesca Corea Chiara Di Resta Rossella Tomaiuolo Nicasio Mancini Massimo Locatelli Mario Plebani Giuseppe Banfi
author_facet	Davide Ferrari Nicola Clementi Elena Criscuolo Alessandro Ambrosi Francesca Corea Chiara Di Resta Rossella Tomaiuolo Nicasio Mancini Massimo Locatelli Mario Plebani Giuseppe Banfi
author_sort	Davide Ferrari
title	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
title_short	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
title_full	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
title_fullStr	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
title_full_unstemmed	Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
title_sort	antibody titer kinetics and sars-cov-2 infections six months after administration with the bnt162b2 vaccine
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/2a53109e5c4446eab4133351448890e3
work_keys_str_mv	AT davideferrari antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT nicolaclementi antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT elenacriscuolo antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT alessandroambrosi antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT francescacorea antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT chiaradiresta antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT rossellatomaiuolo antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT nicasiomancini antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT massimolocatelli antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT marioplebani antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine AT giuseppebanfi antibodytiterkineticsandsarscov2infectionssixmonthsafteradministrationwiththebnt162b2vaccine
_version_	1718410142543773696

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine

Ejemplares similares